ADMA Biologics Realizing the Potential of Specialty Biologics with Groundbreaking Immunotechnology January 2026 NASDAQ: ADMA Forward-Looking Statements This presentation contains "forward-looking statements" pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, about ADMA Biologics, Inc. and its subsidiaries (collectively, "we," "our" or the "Company"), including, without limitation, statements that may predict, forecast, indicate, or imply future results, performan ...

January 9, 2026 Zanidatamab: Pivotal Phase 3 HERIZON-GEA-01 Trial Results in Gastroesophageal Adenocarcinoma (GEA) Innovating to Transform the Lives of Patients and Their Families Intended for U.S. investor audiences only. Intended for U.S. investor audiences only. 2 January 9, 2026 Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the C ...

KalVista Pharmaceuticals Corporate Overview January 2026 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to our management. For this purpose, any statements that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be ...

Financial Performance and Targets - Yara aims for a through-the-cycle Return on Invested Capital (ROIC) exceeding 10%[29] - The company has already delivered >180 MUSD EBITDA increase and is committed to further cash flow improvement[26] - Yara targets >350 MUSD EBITDA improvement and >600 MUSD sustainable cash flow expansion from 2024-2030[27] - L12M EBITDA per 3Q25 reached 2.6 BUSD, a +500 MUSD increase compared to 3Q24[135] - L12M Free cash flow per 3Q25 was 715 MUSD, a +592 MUSD increase compared to 3Q24[135] Market Dynamics and Strategy - Urea demand growth remains consistent, with total nitrogen showing a 1.1% trend growth and urea specifically at 1.7% trend growth[43] - Yara's European finished nitrogen products have >75% flexibility on ammonia source[22, 58, 91, 133, 178] - The company's AdBlue and TAN business has seen a ~160% increase in commercial EBITDA since 2019[97] - Yara's durian solutions in Thailand have led to a 45000 t of NPKs p.a at 40% premium[109] Production and Cost Efficiency - Yara achieved all-time high production volumes, resulting in a ~250 MUSD impact[62] - The company is actively managing its portfolio, with actions taken on all harvest sites resulting in >200 MUSD annual cash flow impact[68] - Yara has achieved >180 MUSD in fixed cost reduction, with a high drop-through impact on EBITDA[27, 168]

Attacking Bladder Cancer for a Better Tomorrow | 1 Disclaimer and Forward -Looking Statements We caution you that this presentation contains forward -looking statements about us and our industry. All statements other than s tatements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, rese arch and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned clinical ...

Q1 FY26 Earnings Results JANUARY 8, 2026 Forward-Looking Statements Historical financial and operating data in this presentation reflect the consolidated results of WD-40 Company and its subsidiaries (collectively, the "Company"). The Company markets maintenance products ("MP") under the WD-40®, 3-IN-ONE® and GT85® brand names. The WD-40 brand portfolio also includes the WD-40® Multi-Use Product, the WD-40 Specialist® and WD-40 BIKE® product lines. The Company markets the homecare and cleaning products ("HC ...

NYSE: GBX 1Q26 Earnings Slides & Supplemental Information InvestorRelations@gbrx.com www.gbrx.com Forward Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements, including statements that are not purely statements of historical fact. The Greenbrier Companies, Inc. (the "Company," "we," "us" or "our") uses words, and variations of words, such as "backlog," "believe," "capacity," "commit," "continue," "drive," "estimate," "expect," "focus," "future," "gr ...

Earnings Call: Q1 - FY26 January 8, 2026 $0.03 Diluted EPS $18.4M Revenue 19% Adj. EBITDA Margin -3% Revenue Decline Current period Prior Year Comparison (1Q25) $0.13 Adj. Diluted EPS $18.9M Revenue $0.01 Diluted EPS 24% Adj. EBITDA Margin +31% $0.17 Revenue Growth Adj. Diluted EPS Trailing Twelve Months (TTM) Highlights ($3.20) Diluted EPS (1) $78.7M Revenue 27% Adj. EBITDA Margin +6% Revenue Growth Current period Prior Year Comparison (1Q25) $0.98 Adj. Diluted EPS $74.4M Revenue $0.40 Diluted EPS 29% Adj. ...

Phase 2 COACH Trial Topline Week 52 Data January 8, 2026 Treatment with TransCon CNP and TransCon hGH combination therapy is investigational. For investor communication only. Not for use in product promotion. Not for further distribution. Cautionary Note on Forward-Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, such as statements regarding TransCon hGH's ability to complement TransCon CNP's ho ...

KB407 for Cystic Fibrosis CORAL-1 Clinical Data Update January 2026 © Copyright 2026 Krystal Biotech, Inc. All rights reserved. Forward Looking Statements and Disclosures This presentation and our discussion contain forward-looking statements that involve substantial risks and uncertainties. Any statements about future expectations, plans, and prospects for Krystal Biotech, Inc. (the "Company"), including but not limited to statements about the Company's investigational product candidate, KB407, and the COR ...